Market failures cause antibiotic resistance. Here's how to address them
Antibiotics have lowered deaths from infectious diseases, but we need to overcome the economic challenges to ensure we continue their future development.
Anthony is a Senior Policy Analyst in CGD’s global health policy team. He leads CGD’s work on antimicrobial resistance (AMR), including modelling the macro-economic burden of AMR and was previously the technical lead of CGD’s working group, A New Grand Bargain to Improve the Antimicrobial Market for Human Health. He has also led projects analysing the COVID-19 vaccine portfolio, examining policy interventions to protect the supply chains for pharmaceuticals from COVID-19-induced shocks, and contributed to the international Decision Support Initiative’s work in Ethiopia
Before joining CGD, he was Head of Economic Research for the UK’s Independent Review into AMR which was set up by the UK government and the Wellcome Trust; led a Wellcome Trust project examining how it could fund more economic research; a research associate at ODI working on the political economy of why governments role out health services in LMICs, (particularly those aimed at reaching the left behind); and a senior health economist at the University of Oxford, modelling the cost of malaria interventions.
Anthony has a master’s in public and economic policy from the London School of Economics, and his undergraduate degree is from Trinity College Dublin.